NCT04890587 - A Phase I Study of AL8326 in Advanced Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

AL8326 tablets

Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.

Trial Locations (2)

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

RECRUITING

Hunan Cancer Hospital, Changsha